IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
Interleukin 12 (IL-12) is a naturally occurring cytokine that plays a key role in inducing antitumor immune responses, including induction of antitumor immune memory. Currently, no IL-12-based therapeutic products have been approved for clinical application because of its toxicities. On the basis of...
Main Authors: | Zhiliang Jia, Dristhi Ragoonanan, Kris Michael Mahadeo, Jonathan Gill, Richard Gorlick, Elizabeth Shpal, Shulin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.952231/full |
Similar Items
-
IL-12 and IL-23—Close Relatives with Structural Homologies but Distinct Immunological Functions
by: Doreen M. Floss, et al.
Published: (2020-09-01) -
The multifaceted role of IL-12 in cancer
by: Um e Habiba, et al.
Published: (2022-10-01) -
Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy
by: Baitao Dou, et al.
Published: (2024-01-01) -
Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
by: Christine M. Minnar, et al.
Published: (2024-01-01) -
IL-12 Family Cytokines in Cancer and Immunotherapy
by: Bhalchandra Mirlekar, et al.
Published: (2021-01-01)